Drug Type Antibody drug conjugate (ADC) |
Synonyms (vic-)trastuzumab-duocarmazine, Anti-HER2 ADC(Byondis), Immunoglobulin g1-kappa, anti-(homo sapiens erbb2 (epidermal growth factor receptor 2, receptor tyrosineprotein kinase erbb-2, egfr2, her2, her-2, p185cerbb2, neu, cd340)), humanized monoclonal antibody conjugated to the pro-drug seco-duocarmycinhydroxyb + [6] |
Target |
Action inhibitors, antagonists |
Mechanism DNA inhibitors(DNA inhibitors), HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedNDA/BLA |
First Approval Date- |
RegulationFast Track (United States) |



| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HER2 Positive Breast Cancer | NDA/BLA | European Union | 12 Jul 2022 | |
| HER2 Positive Breast Cancer | NDA/BLA | European Union | 12 Jul 2022 | |
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | United States | 15 Dec 2017 | |
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | Belgium | 15 Dec 2017 | |
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | Canada | 15 Dec 2017 | |
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | Denmark | 15 Dec 2017 | |
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | France | 15 Dec 2017 | |
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | Italy | 15 Dec 2017 | |
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | Netherlands | 15 Dec 2017 | |
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | Singapore | 15 Dec 2017 |
Phase 3 | 437 | kdsdwkyrqk(iujbnqupti) = ugobjgbkul psfsvxzibr (xytlapjwkp, 5.4 - 7.2) View more | Positive | 10 Feb 2025 | |||
(Physician's Choice (PC)) | kdsdwkyrqk(iujbnqupti) = yxerjcagcd psfsvxzibr (xytlapjwkp, 4.0 - 5.5) View more | ||||||
Phase 2 | 64 | tltgosbzll = povhikkkwt pmrwkfuykh (vwgookbphc, bfnwbrarlr - vtopmfctrp) View more | - | 30 May 2024 | |||
Phase 3 | HER2 Positive Breast Cancer HER2 Positive | 437 | kdttbmhnwg(rcdygcstrq) = hqbkcjxdte kmrjvdkkwv (spjezesgcx ) View more | Superior | 22 Oct 2023 | ||
physician's choice | kdttbmhnwg(rcdygcstrq) = ylfzppmpbs kmrjvdkkwv (spjezesgcx ) View more | ||||||
Phase 3 | 437 | ((Vic-)Trastuzumab Duocarmazine) | knqidebomn(hzzqgrjmbd) = fxwxoogbts dreghqlqaz (oipixfcxiw, vtutnapibf - qajfafzzfz) View more | - | 19 Oct 2023 | ||
(Physician's Choice) | knqidebomn(hzzqgrjmbd) = uhkwoqxkos dreghqlqaz (oipixfcxiw, zpecimzrlr - orfryhlmvh) View more | ||||||
Phase 3 | HER2 Positive Breast Cancer HER2 Positive | 437 | jhdfwkcdfk(smbcnoogix) = byxixoupzf qlwhiykxjw (grrqoghinz, 5.4 - 7.2) View more | Superior | 19 Sep 2021 | ||
physician’s choice treatment | jhdfwkcdfk(smbcnoogix) = wiaiddgtcw qlwhiykxjw (grrqoghinz ) View more | ||||||
NCT02277717 (Pubmed) Manual | Phase 1 | 185 | (dose-escalation) | cylscsapve(rivvhsupux) = rfgywihbmh puxhnapexs (sgctufnvgl ) | Positive | 01 Aug 2019 | |
(dose-expansion) | dautfofleb(mhyayjlanl) = bazqexysfx zgnuisiigp (cgaulrxtlx, 20.4 - 48.4) View more | ||||||
Phase 1 | 99 | gzgamqkmbc(fudfspqfvs) = ofkpgsevqa ucqtxlhvpv (mzhcnuodwo ) View more | Positive | 01 Jun 2018 | |||
Phase 1 | Metastatic human epidermal growth factor 2 positive carcinoma of breast HER2-positive | HER2-negative | - | fnzdguutka(rkpniiafzd) = conjunctivitis, stomatitis, fatigue, and decreased appetite qgblyofiaz (ggdbciijhz ) View more | Positive | 15 Feb 2017 | ||
Placebo |






